Posts
- Care home feasibility study shows Lodestar's impact on resident treatment
- Llusern announce two exciting commercial partnerships to improve UTI diagnosis
- Llusern bags a hat-trick at ICS 2026.
- Two abstracts published in The Journal of Urology.
- Llusern announces changes to Exec team and new NED
- Introducing Lodestar UTI into your clinic. Download this handy guide today.
- Llusern to attend WHX Dubai 9-12 February 2026
- Lodestar UTI to be presented at two major urology congresses
- Mobile community UTI testing arrives in Glasgow in 2026
- Quick and accurate UTI diagnostics make for better clinical decisions
- New webinar: A real-world performance study of the Lodestar UTI testing system
- New study data demonstrates Lodestar more accurate than lab culture
- Barclays Entrepreneur of the Year and Beyond Biotech podcast
- New antibiogram data shows Lodestar covers 96% of UTI pathogens
- A perfect partnership at The Forbury Clinic
- Llusern Scientific Announces Key Appointments to Strengthen its Executive Team
- Lodestar DX helps reduce antibiotic use at elderly care home
- Llusern Scientific announces ISO 13485 certification
- Llusern grabs the limelight at Arab Health 2025
- Study shows Lodestar DX accurately identifies uropathogens in mixed growth cultures
- Llusern secures pre-Seed investment from DBW
- Llusern's Lodestar DX Evaluation Published in JAC-AMR: Demonstrating High Correlation with Gold Standard UTI Testing
- Longitude Prize on AMR
- Bio 2024, San Diego
- Two abstracts published by JAC-AMR
- Poster presentations at BSAC UTI conference
- Llusern at ECCMID23 in Copenhagen
- Women feel ‘failed’ by UTI testing system – ITV News
- Llusern included in NICE early value assessment for UTI testing
- Llusern win at MediWales Awards 2022
- Radio 4’s Woman’s Hour talk UTIs with Llusern
- Llusern wins at the Wales STEM Awards
- UTI test undergoing clinical verification and validation
- CEO awarded top prize to develop UTI test
